Botulinum neurotoxin serotype F: Identification of substrate recognition requirements and development of inhibitors with low nanomolar affinity

被引:41
作者
Schmidt, JJ [1 ]
Stafford, RG [1 ]
机构
[1] USA, Med Res Inst Infect Dis, Div Toxicol, Ft Detrick, MD 21702 USA
关键词
D O I
10.1021/bi0477642
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Botulinum neurotoxins (BoNTs A-G) are zinc metalloendoproteases that exhibit extraordinary specificities for proteins involved in neurotransmitter release. In view of the extreme toxicities of these molecules, their applications in human medicine, and potential for misuse, it is of considerable importance to elucidate the mechanisms underlying substrate recognition and to develop inhibitors, with the ultimate goal of obtaining anti-botulinum drugs. We synthesized peptides based on vesicle-associated membrane protein (VAMP) to investigate the substrate requirements of BoNT F, which cleaves VAMP between residues Q58 and K59. The minimum substrate was a peptide containing VAMP residues 32-65, which includes only one of the two VAMP structural motifs thought to be required for botulinum substrate recognition. BoNT F exhibited a strict requirement for residues D57 (P-2), K59 (P-1'), and L60 (P-2'), but peptides containing substitutions for R56 (P-3) Q58 (P-1), and S61 (P-3') were cleaved. Therefore, the P2, P-1', and P-2' residues of VAMP are of paramount importance for BoNT F substrate recognition near the scissile bond. K-i values of uncleavable analogues were similar to K,,, values of the substrate, suggesting that substrate discrimination occurs at the cleavage step, not at the initial binding step. We then synthesized inhibitors of BoNT F that incorporated D-cysteine in place of glutamine 58, exhibited Ki values of 1-2 nM, and required binding groups on the N-terminal but not the C-terminal side of the zinc ligand. The latter characteristic distinguishes BoNT F from other zinc metalloendoproteases, including BoNTs A and B.
引用
收藏
页码:4067 / 4073
页数:7
相关论文
共 57 条
  • [1] Protection by the heavy metal chelator N,N,N',N'-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B
    Adler, M
    Dinterman, RE
    Wannemacher, RW
    [J]. TOXICON, 1997, 35 (07) : 1089 - 1100
  • [2] Adler M, 1999, J APPL TOXICOL, V19, pS5, DOI 10.1002/(SICI)1099-1263(199912)19:1+<S5::AID-JAT606>3.0.CO
  • [3] 2-M
  • [4] Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity
    Adler, M
    Nicholson, JD
    Hackley, BE
    [J]. FEBS LETTERS, 1998, 429 (03) : 234 - 238
  • [5] High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity
    Anne, C
    Cornille, F
    Lenoir, C
    Roques, BP
    [J]. ANALYTICAL BIOCHEMISTRY, 2001, 291 (02) : 253 - 261
  • [6] Botulinum toxin as a biological weapon - Medical and public health management
    Arnon, SS
    Schechter, R
    Inglesby, TV
    Henderson, DA
    Bartlett, JG
    Ascher, MS
    Eitzen, E
    Fine, AD
    Hauer, J
    Layton, M
    Lillibridge, S
    Osterholm, MT
    O'Toole, T
    Parker, G
    Perl, TM
    Russell, PK
    Swerdlow, DL
    Tonat, K
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08): : 1059 - 1070
  • [7] A novel strategy for designing specific gelatinase A inhibitors:: potential use to control tumor progression
    Augé, F
    Hornebeck, W
    Laronze, JY
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 49 (03) : 277 - 282
  • [8] Dual toxin-producing strain of Clostridium botulinum type Bf isolated from a California patient with infant botulism
    Barash, JR
    Arnon, SS
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (04) : 1713 - 1715
  • [9] 1.8-angstrom crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate prime-side inhibitor with a distinct selectivity profile
    Betz, M
    Huxley, P
    Davies, SJ
    Mushtaq, Y
    Pieper, M
    Tschesche, H
    Bode, W
    GomisRuth, FX
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 247 (01): : 356 - 363
  • [10] Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity
    Blommaert, A
    Turcaud, S
    Anne, C
    Roques, BP
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (11) : 3055 - 3062